research Non-invasive analysis of penetration and storage of Isoconazole nitrate in the stratum corneum and the hair follicles
Isoconazole nitrate stays effective in skin and hair follicles for up to two weeks after use.
Search
for
Sort by
Research
990-1000 / 1000+ results
research New tool in our arsenal: efficacy of injectable platelet-rich fibrin (i-PRF) in androgenetic alopecia treatment
Injectable platelet-rich fibrin effectively improves hair density and scalp symptoms in androgenetic alopecia.
research Nutritional Significance of Inositol and Biotin for the Pig
Biotin and inositol are crucial for pig health and growth.
research Use of Myoinositol in PCOS
Myoinositol effectively manages PCOS with fewer side effects than metformin.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
JAK inhibitors are generally safe for alopecia areata and atopic dermatitis, with mostly mild side effects.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.